Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Head & Neck 1Gynecologic 1Gastrointestinal 1Breast 1

Conditions

Head and Neck Neoplasms 2Triple Negative Breast Neoplasms 1Thyroid Cancer, Papillary 1Stomach Neoplasms 1Squamous Cell Carcinoma of Head and Neck 1Pancreatic Neoplasms 1Ovarian Neoplasms 1Colorectal Neoplasms 1Carcinoma, Medullary 1

Interventions

pembrolizumab 31Nivolumab 11Ipilimumab 6spartalizumab 5cemiplimab 5atezolizumab 5Gemcitabine 4Docetaxel 4durvalumab 3budigalimab 3avelumab 3Oxaliplatin 3Leucovorin 3Irinotecan 3Immune Checkpoint Inhibitors 3Fluorouracil 3Cyclophosphamide 3Cetuximab 3Carboplatin 3130-nm albumin-bound paclitaxel 3obinutuzumab 2lenvatinib 2fludarabine 2epacadostat 2X-Rays 2Paclitaxel 2Immunoglobulin G 2Cisplatin 2Capecitabine 2Biopsy 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Triple Negative Breast Neoplasms × Ferrosoferric Oxide × Head & Neck × Clear all
NCT01770353 2019-11-27

MM-398 (Nanoliposomal Irinotecan, Nal-IRI) to Determine Tumor Drug Levels and to Evaluate the Feasibility of Ferumoxytol Magnetic Resonance Imaging to Measure Tumor Associated Macrophages and to Predict Patient Response to Treatment

Ipsen

Phase 1 Completed
45 enrolled 33 charts
BreastGastrointestinalGynecologicHead & Neck

Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡